Medical Oncology Hematology Consultants PA
in ChristianaCare Helen F. Graham Cancer Center & Research Institute
Newark, DE
Accepting patients
MonumenTAL-6
64407564MMY3009: A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pom
- Bispecific Antibody
- GPRC5D
- CD3
- Randomization
- Phase 3
Accepting patients
Teclistamab or Talquetamab
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
- Bispecific Antibody
- BCMA
- Phase 2
- Has results